Other Neuroscience — Net revenues
Products & Services · Net revenuesAbbVie Other Neuroscience — Net revenues increased by 2.2% to $47.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 53.0%, from $100.00M to $47.00M. Over 4 years (FY 2021 to FY 2025), Other Neuroscience — Net revenues shows a downward trend with a -25.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration or growth in secondary neurological therapies, while a decrease may signal product lifecycle maturity or competitive pressure in these niche segments.
Detailed definition
This metric represents the total net sales generated from the company's secondary portfolio of neuroscience therapeutic...
Peer comparison
Peers in the pharmaceutical industry typically report similar secondary segment revenues to demonstrate portfolio depth and diversification beyond their primary blockbuster drugs.
abbv_segment_other_neuroscience_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $171.00M | $171.00M | $183.00M | $177.00M | $150.00M | $87.00M | $61.00M | $79.00M | $70.00M | $61.00M | $66.00M | $74.00M | $80.00M | $84.00M | $100.00M | $59.00M | $55.00M | $46.00M | $47.00M |
| QoQ Change | — | +0.0% | +7.0% | -3.3% | -15.3% | -42.0% | -29.9% | +29.5% | -11.4% | -12.9% | +8.2% | +12.1% | +8.1% | +5.0% | +19.0% | -41.0% | -6.8% | -16.4% | +2.2% |
| YoY Change | — | — | — | — | -12.3% | -49.1% | -66.7% | -55.4% | -53.3% | -29.9% | +8.2% | -6.3% | +14.3% | +37.7% | +51.5% | -20.3% | -31.3% | -45.2% | -53.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's other neuroscience — net revenues?
- AbbVie (ABBV) reported other neuroscience — net revenues of $47.00M in Q4 2025.
- How has AbbVie's other neuroscience — net revenues changed year-over-year?
- AbbVie's other neuroscience — net revenues decreased by 53.0% year-over-year, from $100.00M to $47.00M.
- What is the long-term trend for AbbVie's other neuroscience — net revenues?
- Over 4 years (2021 to 2025), AbbVie's other neuroscience — net revenues has grown at a -25.9% compound annual growth rate (CAGR), from $685.00M to $207.00M.
- What does other neuroscience — net revenues mean?
- Total revenue generated from the company's secondary portfolio of neuroscience pharmaceutical products.